Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
- 1 September 2021
- journal article
- letter
- Published by Elsevier in Microbes and Infection
- Vol. 23 (8) , 104840
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China
This publication has 7 references indexed in Scilit:
- Antivirals with common targets against highly pathogenic virusesCell, 2021
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionCell Research, 2020
- Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike proteinCellular & Molecular Immunology, 2020
- Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41AIDS, 2019
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spikeScience Advances, 2019
- Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation VaccinesCell, 2018
- ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimerBiochimica et Biophysica Acta (BBA) - Biomembranes, 2014